Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Current Assets (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Current Assets data on record, last reported at $44.1 million in Q3 2025.

  • For Q3 2025, Current Assets fell 24.18% year-over-year to $44.1 million; the TTM value through Sep 2025 reached $44.1 million, down 24.18%, while the annual FY2024 figure was $51.7 million, 45.2% down from the prior year.
  • Current Assets reached $44.1 million in Q3 2025 per SGMO's latest filing, down from $49.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $606.9 million in Q1 2021 and bottomed at $37.6 million in Q1 2025.
  • Average Current Assets over 5 years is $226.6 million, with a median of $159.6 million recorded in 2023.
  • Peak YoY movement for Current Assets: surged 63.62% in 2021, then plummeted 74.89% in 2024.
  • A 5-year view of Current Assets shows it stood at $398.8 million in 2021, then decreased by 24.69% to $300.3 million in 2022, then tumbled by 68.59% to $94.3 million in 2023, then plummeted by 45.2% to $51.7 million in 2024, then dropped by 14.73% to $44.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $44.1 million in Q3 2025, $49.9 million in Q2 2025, and $37.6 million in Q1 2025.